Peptide YY: Food for thought

Physiology and Behavior

Volumn 97, Issue 5, 2009, Pages 616-619

  Neary, Marianne T ^a   Batterham, Rachel L ^a  

^a NONE

Author keywords

Appetite; Bariatric surgery; Energy homeostasis; Gut hormones; Obesity; Peptide YY; Reward

Indexed keywords

ANTIOBESITY AGENT; GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 1; NEUROPEPTIDE Y2 RECEPTOR AGONIST; PEPTIDE YY; PEPTIDE YY [3-36]; RIMONABANT; UNCLASSIFIED DRUG;

ANOREXIA; APPETITE; ARTICLE; ASSOCIATION; BARIATRIC SURGERY; BODY MASS; DIET RESTRICTION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SYNTHESIS; ENERGY BALANCE; ENERGY EXPENDITURE; EXERCISE; FAT INTAKE; FEEDING BEHAVIOR; FOOD INTAKE; HOMEOSTASIS; HORMONE ACTION; HUMAN; HYPERPHAGIA; LIMBIC CORTEX; MORBID OBESITY; MUSCLE ATROPHY; NONHUMAN; OBESITY; PANDEMIC; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; REGULATORY MECHANISM; ROUX Y ANASTOMOSIS; STOMACH BYPASS; THERMOGENESIS; VAGUS NERVE STIMULATION; WAIST CIRCUMFERENCE;

ANIMALS; APPETITE REGULATION; ENERGY METABOLISM; HUMANS; MICE; OBESITY; PEPTIDE YY;

EID: 68649116036     PISSN: 00319384     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.physbeh.2009.02.024     Document Type: Article

References (50)

1. Cummings D.E., and Overduin J. Gastrointestinal regulation of food intake. J Clin Invest 117 (2007) 13-23
2. Tatemoto K., and Mutt. V. Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides 285 (1980) 417-418
3. Tatemoto K. Isolation and characterization of peptide YY (PYY), a candidate gut hormone that inhibits pancreatic exocrine secretion. Proc Natl Acad Sci U S A 79 (1982) 2514-2518
4. Batterham R.L., Heffron H., Kapoor S., Chivers J.E., Chandarana K., Herzog H., et al. Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metabolism 4 (2006) 223-233
5. Korner J., Inabnet W., Conwell I.M., Taveras C., Daud A., Olivero-Rivera L., et al. Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels. Obesity 14 (2006) 1553-1561
6. Chelikani P.K., Haver A.C., and Reidelberger R.D. Intravenous infusion of peptide YY(3-36) potently inhibits food intake in rats. Endocrinology 146 (2005) 879-888
7. Adrian T.E., FG, Bacarese-Hamilton A.J., Fuessl H.S., Polak J.M., and Bloom S.R. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 89 (1985) 1070-1077
8. Helou N., Obeid O., Azar S.T., and Hwalla N. Variation of postprandial PYY 3-36 response following ingestion of differing macronutrient meals in obese females. Ann Nutr Metab 52 (2008) 188-195
9. Adrian T.E., Savage A.P., Sagor G.R., Allen J.M., Bacarese-Hamilton A.J., Tatemoto K., Polak J.M., et al. Effect of peptide YY on gastric, pancreatic, and biliary function in humans. Gastroenterology 89 (1985) 494-499
10. Batterham R.L., Cohen M.A., Ellis S.M., Le Roux C.W., Withers D.J., Frost G.S., et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 349 (2003) 941-948
11. Batterham R.L., Cowley M.A., Small C.J., Herzog H., Cohen M.A., Dakin C.L., et al. Gut hormone PYY3-36 physiologically inhibits food intake 418 (2002) 650-654
12. Abbott C.R., Small C.J., Kennedy A.R., Neary N.M., Sajedi A., Ghatei M.A., et al. Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY(3-36) on food intake. Brain Res 1043 (2005) 139-144
13. Challis B.G., Pinnock S.B., Coll A.P., Carter R.N., Dickson S.L., and O'Rahilly S. Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse. Biochem Biophys Res Commun 311 (2003) 915-919
14. Chelikani P.K., Haver A.C., and Reidelberger R.D. Comparison of the inhibitory effects of PYY(3-36) and PYY(1-36) on gastric emptying in rats. Am J Physiol Regul Integr Comp Physiol 287 (2004) R1064-R1070
15. Koda S., Date Y., Murakami N., Shimbara T., Hanada T., Toshinai K., et al. The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats. Endocrinology 146 (2005) 2369-2375
16. Pittner R.A., Moore C.X., Bhavsar S.P., Gedulin B.R., Smith P.A., Jodka C.M., et al. Effects of PYY[3-36] in rodent models of diabetes and obesity. Int J Obes Relat Metab Disord 28 (2004) 963-971
17. Scott V., Kimura N., Stark J.A., and Luckman S.M. Intravenous peptide YY3-36 and Y2 receptor antagonism in the rat: effects on feeding behaviour. J Neuroendocrinol 17 (2005) 452-457
18. Unniappan S., and Kieffer T.J. Leptin extends the anorectic effects of chronic PYY(3-36) administration in ad libitum-fed rats. Am J Physiol Regul Integr Comp Physiol 295 (2008) R51-R58
19. Vrang N., Madsen A.N., Tang-Christensen M., Hansen G., and Larsen P.J. PYY(3-36) reduces food intake and body weight and improves insulin sensitivity in rodent models of diet-induced obesity. Am J Physiol Regul Integr Comp Physiol 291 (2006) R367-R375
20. Koegler F.H., Enriori P.J., Billes S.K., Takahashi D.L., Martin M.S., Clark R.L., et al. Peptide YY(3-36) inhibits morning, but not evening, food intake and decreases body weight in rhesus macaques. Diabetes 54 (2005) 3198-3204
21. Batterham R.L., ffytche D.H., Rosenthal J.M., Zelaya F.O., Barker G.J., Withers D.J., et al. PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans. Nature 450 (2007) 106-109
22. le Roux C.W., Batterham R.L., Aylwin S.J.B., Patterson M., Borg C.M., Wynne K.J., et al. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 147 (2006) 3-8
23. Sloth B., Holst J.J., Flint A., Gregersen N.T., and Astrup A. Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects. Am J Physiol Endocrinol Metab 292 (2007) E1062-E1068
24. Ortiz A.A., Milardo L.F., Decarr L.B., Buckholz T.M., Mays M.R., Claus T.H., et al. A novel long-acting selective neuropeptide Y2 receptor PEGylated peptide agonist reduces food intake and body weight and improves glucose metabolism in rodents. J Pharmacol Exp Ther 323 2 (2007) 692-700
25. Abbott C.R., Monteiro M., Small C.J., Sajedi A., Smith K.L., Parkinson J.R., et al. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 1044 (2005) 127-131
26. Halatchev I.G., and Cone R.D. Peripheral administration of PYY(3-36) produces conditioned taste aversion in mice. Cell Metab 1 (2005) 159-168
27. Talsania T., Anini Y., Siu S., Drucker D.J., and Brubaker P.L. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 146 (2005) 3748-3756
28. Friedman M.I. Fuel partitioning and food intake. Am J Clin Nutr 67 (1998) 513S-518S
29. van den Hoek A.M., Heijboer A.C., Corssmit E.P., Voshol P.J., Romijn J.A., Havekes L.M., et al. PYY3-36 reinforces insulin action on glucose disposal in mice fed a high-fat diet. Diabetes 53 (2004) 1949-1952
30. Adams S.H., Lei C., Jodka C.M., Nikoulina S.E., Hoyt J.A., Gedulin B., et al. PYY[3-36] administration decreases the respiratory quotient and reduces adiposity in diet-induced obese mice. J Nutr 136 (2006) 195-201
31. van den Hoek A.M., Heijboer A.C., Voshol P.J., Havekes L.M., Romijn J.A., Corssmit E.P., et al. Chronic PYY3-36 treatment promotes fat oxidation and ameliorates insulin resistance in C57BL6 mice. Am J Physiol Endocrinol Metab 292 (2007) E238-E245
32. Boey D., Lin S., Enriquez R.F., Lee N.J., Slack K., Couzens M., et al. PYY transgenic mice are protected against diet-induced and genetic obesity. Neuropeptides 42 (2008) 19-30
33. Guo Y., Ma L., Enriori P.J., Koska J., Franks P.W., Brookshire T., et al. Physiological evidence for the involvement of peptide YY in the regulation of energy homeostasis in humans. Obesity (Silver Spring) 14 (2006) 1562-1570
34. Alvarez Bartolome M., Borque M., Martinez-Sarmiento J., Aparicio E., Hernandez C., Cabrerizo L., et al. Peptide YY secretion in morbidly obese patients before and after vertical banded gastroplasty. Obes Surg 12 (2002) 324-327
35. Roth J., Coffey T., Jodka C., Maier H., Athanacio J., Mack C., et al. Combination therapy with amylin and PYY[3 36] in obese rodents: anorexigenic synergy and weight loss additivity. Endocrinology 148 12 (2007) 6054-6061
36. Siahanidou T., Mandyla H., Vounatsou M., Anagnostakis D., Papassotiriou I., and Chrousos G.P. Circulating peptide YY concentrations are higher in preterm than full-term infants and correlate negatively with body weight and positively with serum ghrelin concentrations. Clin Chem 51 (2005) 2131-2137
37. Misra M., Miller K.K., Tsai P., Gallagher K., Lin A., Lee N., et al. Elevated peptide YY levels in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab 91 (2006) 1027-1033
38. Pfluger P.T., Kampe J., Castaneda T.R., Vahl T., D'Alessio D.A., Kruthaupt T., et al. Effect of human body weight changes on circulating levels of peptide YY and peptide YY3-36. J Clin Endocrinol Metab 92 (2007) 583-588
39. Yang N., Wang C., Xu M., Mao L., Liu L., and Sun X. Interaction of dietary composition and PYY gene expression in diet-induced obesity in rats. J Huazhong Univ Sci Technolog Med Sci 25 (2005) 243-246
40. Morinigo R., Moize V., Musri M., Lacy A.M., Navarro S., Marin J.L., et al. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 91 (2006) 1735-1740
41. Naslund E., Gryback P., Hellstrom P.M., Jacobsson H., Holst J.J., Theodorsson E., et al. Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity. Int J Obes Relat Metab Disord 21 (1997) 387-392
42. Chan J.L., Mun E.C., Stoyneva V., Mantzoros C.S., and Goldfine A.B. Peptide YY levels are elevated after gastric bypass surgery. Obesity 14 (2006) 194-198
43. Korner J., Bessler M., Cirilo L.J., Conwell I.M., Daud A., Restuccia N.L., et al. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab 90 (2005) 359-365
44. le Roux C.W., Aylwin S.J., Batterham R.L., Borg C.M., Coyle F., Prasad V., et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 243 (2006) 108-114
45. Strader A.D., Vahl T.P., Jandacek R.J., Woods S.C., D'Alessio D.A., and Seeley R.J. Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats. Am J Physiol Endocrinol Metab 288 (2005) E447-E453
46. Lumb K.J., DeCarr L.B., Milardo L.F., Mays M.R., Buckholz T.M., Fisk S.E., et al. Novel selective neuropeptide Y2 receptor PEGylated peptide agonists reduce food intake and body weight in mice. J Med Chem 50 (2007) 2264-2268
47. Balasubramaniam A., Joshi R., Su C., Friend L.A., and James J.H. Neuropeptide Y (NPY) Y2 receptor-selective agonist inhibits food intake and promotes fat metabolism in mice: combined anorectic effects of Y2 and Y4 receptor-selective agonists. Peptides NPY and cohorts in human disease. Proceedings of the 8th International NPY meeting 2006 vol. 28 (2007) 235-240
48. White N.E., Dhillo W.S., Liu Y.L., Small C.J., Kennett G.A., Gardiner J.V., et al. Co-administration of SR141716 with peptide YY(3-36) or oxyntomodulin has additive effects on food intake in mice. Diabetes Obes Metab 10 2 (2008) 167-170
49. Neary N.M., Small C.J., Druce M.R., Park A.J., Ellis S.M., Semjonous N.M., et al. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 146 (2005) 5120-5127
50. Broom D.R., Batterham R.L., King J.A., and Stensel D.J. The influence of resistance and aerobic exercise on hunger, circulating levels of acylated ghrelin and peptide YY in healthy males. Am J Physiol Regul Integr Comp Physiol 296 1 (2009) R29-R35